Earnings ·
10x Genomics reported second quarter 2026 financial results with revenue of $151.0 million, a decline from $172.9…
TXG10x Genomics, Inc.
10x Genomics reported second quarter 2026 financial results with revenue of $151.0 million, a decline from $172.9 million in the prior year period. Excluding non-recurring patent litigation settlement revenues of $1.6 million and $27.3 million respectively, organic revenue increased 3%. The company reported an operating loss of $19.6 million compared to operating income of $30.1 million previously, driven by a lower gain on settlement. Full-year 2026 revenue guidance was raised to $610–$630 million from the previous range of $600–$625 million. The company also announced the acquisition of Proteintech Genomics and new research collaborations with Cleveland Clinic and Lausanne University Hospital. Cash and marketable securities stood at $552.0 million as of June 30, 2026. 10x Genomics operates in the life science technology industry, developing integrated instruments, consumables, and software for single cell and spatial biology research.